Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial.

被引：0

作者：

Fukasawa, Satoshi

Suzuki, Hiroyoshi

Sato, Fuminori

Hashine, Katsuyoshi

Hasumi, Hisashi

Matsumoto, Hiroaki

Tsuchiya, Tomohiro

Uemura, Hirotsugu

Oya, Mototsugu

Kanayama, Hiroomi

Kawaguchi, Kazushiro

Noguchi, Hidehisa

Enjo, Kentaro

Tran, Namphuong

Todd, Mary Beth

Fizazi, Karim

Matsubara, Nobuaki

机构：

[1] Chiba Canc Ctr Hosp, Chiba, Japan

[2] Toho Univ, Sakura Med Ctr, Sakura, Japan

[3] Oita Univ, Oita, Japan

[4] Natl Hosp Org Shikoku Canc Ctr, Matsuyama, Ehime, Japan

[5] Yokohama City Univ, Grad Sch Med, Yokohama, Kanagawa, Japan

[6] Yamaguchi Univ, Grad Sch Med, Ube, Yamaguchi, Japan

[7] Gifu Univ, Grad Sch Med, Gifu, Japan

[8] Kinki Univ, Sch Med, Osaka, Japan

[9] Keio Univ, Sch Med, Tokyo, Japan

[10] Tokushima Univ, Grad Sch, Tokushima, Japan

[11] Janssen Pharmaceut K K, Tokyo, Japan

[12] Janssen Pharmaceut K K, Chiyoda Ku, Tokyo, Japan

[13] Janssen Res Dev, LLC, Los Angeles, CA USA

[14] Janssen Global Serv, Raritan, NJ USA

[15] Univ Paris Sud, Gustave Roussy Inst Oncol, Villejuif, France

[16] Natl Canc Ctr Hosp E, Chiba, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期

关键词：

D O I：

10.1200/JCO.2018.36.6_suppl.286

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

286

引用

页数：1

共 50 条

[1] Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study
Fukasawa, Satoshi
Suzuki, Hiroyoshi
Kawaguchi, Kazushiro
Noguchi, Hidehisa
Enjo, Kentaro
Tran, Namphuong
Todd, Mary
Fizazi, Karim
Matsubara, Nobuaki
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (11) : 1012 - 1021
[2] Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study
Suzuki, Hiroyoshi
Shin, Toshitaka
Fukasawa, Satoshi
Hashine, Katsuyoshi
Kitani, Sumiko
Ohtake, Noriyuki
Shibayama, Kazuhiro
Tran, Namphuong
Mundle, Suneel
Fizazi, Karim
Matsubara, Nobuaki
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (07) : 810 - 820
[3] LATITUDE, a phase 3 double-blind, randomized trial of androgen deprivation therapy (ADT) with abiraterone acetate (AA) plus prednisone (P) or placebos (PBOs) in patients (pts) with newly diagnosed high-risk metastatic hormone-naive prostate cancer (mHNPC)
Feyerabend, S.
Tran, N.
Fein, L.
Matsubara, N.
Rodriguez Antolin, A.
Alekseev, B.
Ozguroglu, M.
Ye, D.
Protheroe, A.
De Porre, P.
Kheoh, T.
Park, Y. C.
Todd, M.
Chi, K.
Fizazi, K.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 113 - 113
[4] Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC).
Fizazi, Karim
Larsen, Julie S.
Matheny, Shannon
Molina, Arturo
Li, Jinhui
Todd, Mary Beth
Yu, Margaret K.
Kheoh, Thian San
Namphuong Tran
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[5] Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial
Buelens, Sarah
Poelaert, Filip
Dhondt, Bert
Fonteyne, Valerie
De Visschere, Pieter
Ost, Piet
Verbeke, Sofie
Villeirs, Geert
De Man, Kathia
Rottey, Sylvie
Decaestecker, Karel
Lumen, Nicolaas
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (04) : 158.e13 - 158.e20
[6] Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial.
Fizazi, Karim
Feyerabend, Susan
Matsubara, Nobuaki
Ozguroglu, Mustafa
Fein, Luis Enrique
Antolin, Alfredo Rodriguez
Alekseev, Boris Yakovlevich
Sulur, Giri
Protheroe, Andrew
De Porre, Peter
Li, Susan
Park, Youn C.
Mundle, Suneel
Tran, Namphuong
Chi, Kim N.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[7] LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer
Fizazi, Karim
Tran, Namphuong
Fein, Luis Enrique
Matsubara, Nobuaki
Antolin, Alfredo Rodriguez
Alekseev, Boris Y.
Ozguroglu, Mustafa
Ye, Dingwei
Feyerabend, Susan
Protheroe, Andrew
De Porre, Peter
Kheoh, Thian
Park, Youn C.
Todd, Mary Beth
Chi, Kim N.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[8] Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial.
Fizazi, Karim
Tran, Namphuong
Fein, Luis Enrique
Matsubara, Nobuaki
Bjartell, Anders
Galli, Luca
Lee, Jae-Lyun
Mazhar, Danish
North, Scott A.
Olmos, David
Suttmann, Henrik
Zou, Qing
Li, Susan
Martin, Jason L.
Park, Youn C.
Sulur, Giri
Deprince, Kris
De Porre, Peter
Chi, Kim N.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[9] Cost-effectiveness analysis of abiraterone acetate (AA) versus docetaxel (D) for the management of metastatic hormone naive prostate cancer (mHNPC)
Ramamurthy, Chethan
Correa, Andres F.
Handorf, Elizabeth A.
Beck, J. Robert
Geynisman, Daniel M.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[10] LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.
Fizazi, Karim
Namphuong Tran
Enrique Fein, Luis
Matsubara, Nobuaki
Rodriguez Antolin, Alfredo
Alekseev, Boris Y.
Ozguroglu, Mustafa
Ye, Dingwei
Feyerabend, Susan
Protheroe, Andrew
De Porre, Peter
Kheoh, Thian
Park, Youn C.
Todd, Mary Beth
Chi, Kim N.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18)

← 1 2 3 4 5 →